Stockscreener 앱 받기
113.56
3.45%
-4.06
시장 영업 전:
113.70
0.14
+0.12%
전일 마감가:
$117.62
열려 있는:
$119.58
하루 거래량:
1.73M
Relative Volume:
2.42
시가총액:
$7.58B
수익:
$136.86M
순이익/손실:
$-168.69M
주가수익비율:
-40.41
EPS:
-2.81
순현금흐름:
$-113.49M
1주 성능:
+8.57%
1개월 성능:
+15.97%
6개월 성능:
+80.20%
1년 성능:
+103.95%
1일 변동 폭
$109.59
$119.58
1주일 범위
$99.96
$122.20
52주 변동 폭
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
RYTM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
113.56 | 7.85B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 개시 | Citigroup | Buy |
| 2025-11-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $167.00 at Citizens Jmp - MarketBeat
Rhythm advances lead asset into late-stage trial in Prader-Willi syndrome - MSN
Alkeon Capital Management LLC Grows Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Citizens Maintains Rhythm Pharmaceuticals (RYTM) Market Outperform Recommendation - Nasdaq
Canaccord Genuity Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
RYTM Stock: Canaccord Genuity Raises Price Target to $141, Maint - GuruFocus
Goldman Sachs Raises Price Target for RYTM to $157, Maintains Bu - GuruFocus
Goldman Sachs Raises Price Target for RYTM to $157, Maintains Buy Rating | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - MSN
Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on positive PWS data - Investing.com Canada
Rhythm Pharma Surprises With Encouraging PWS Drug Trial Results - Finimize
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says - marketscreener.com
RYTM Analyst Rating Update: Citizens Raises Price Target to $167 - GuruFocus
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $150 From $129, Keeps Overweight Rating - marketscreener.com
Rhythm Pharmaceuticals stock price target raised to $167 at Citizens By Investing.com - Investing.com Canada
Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals - TipRanks
Rhythm Pharmaceuticals stock price target raised to $167 at Citizens - Investing.com India
Rhythm Pharmaceuticals stock jumps as Goldman Sachs raises price target on PWS study - Investing.com Canada
Rhythm Pharmaceuticals (RYTM): Reassessing Valuation After Positive Prader-Willi Data and Phase 3 Trial Plans - Yahoo Finance
Is It Too Late to Invest in Rhythm Pharmaceuticals After Its 2025 Rally? - Yahoo Finance
Growth or Bubble? Exploring Rhythm’s Recent Surge - StocksToTrade
Rhythm Pharmaceuticals stock hits all-time high at 116.08 USD By Investing.com - Investing.com Canada
Needham Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
Rhythm Pharma Soars with Buy Rating and Optimistic Trials - StocksToTrade
Rhythm Pharmaceuticals’ Stock Surge: Buy Now? - timothysykes.com
Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster (RYTM) - Seeking Alpha
Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win - Investor's Business Daily
Rhythm Pharmaceuticals reports positive results in Prader-Willi trial By Investing.com - Investing.com South Africa
Morgan Stanley raises Rhythm Pharmaceuticals stock price target to $150 By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals stock holds Buy rating at TD Cowen on PWS trial data - Investing.com UK
Rhythm Pharmaceuticals Surges: Strategic Moves Fuel Market Buzz - timothysykes.com
Needham Raises Price Target for Rhythm Pharmaceuticals (RYTM) to $145 | RYTM Stock News - GuruFocus
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise - Benzinga
Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 12-Month HighHere's Why - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 1-Year HighWhat's Next? - MarketBeat
Rhythm Pharmaceuticals stock rises after positive study data for setmelanotide in treating genetic disorder - MSN
RYTM: Setmelanotide showed promising BMI and hyperphagia improvements in PWS, supporting phase 3 plans - TradingView
Rhythm Pharmaceuticals (RYTM) Soars Over 15% in Market Rally - GuruFocus
Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder - Stocktwits
Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday - Benzinga
Rhythm Pharmaceuticals (RYTM) Climbs Over 11% - GuruFocus
Citi Initiates Buy Coverage on Rhythm Pharmaceuticals with Price Target Set for Growth - timothysykes.com
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook - ts2.tech
Rhythm Pharmaceuticals Stock Climbs on Positive Trial News - TipRanks
Rhythm Pharmaceuticals stock soars after positive trial results By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals stock soars after positive trial results - Investing.com India
Rhythm Pharmaceuticals stock hits all-time high at 116.08 USD - Investing.com
Rhythm Pharma rises on positive mid-stage data for rare disease therapy - TradingView — Track All Markets
Rhythm Pharmaceuticals reports positive results in Prader-Willi trial - Investing.com
Rhythm Pharmaceuticals Announces Preliminary Phase 2 Trial Results for Setmelanotide in PWS - TradingView — Track All Markets
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):